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9Objectives: Mathematical modeling is used widely in eco-
nomic evaluations of pharmaceuticals and other health-
care technologies. Users of models in government and 
the private sector need to be able to evaluate the quality
of models according to scientiﬁc criteria of good practice.
This report describes the consensus of a task force con-
vened to provide modelers with guidelines for conducting
and reporting modeling studies.
Methods: The task force was appointed with the advice
and consent of the Board of Directors of ISPOR.
Members were experienced developers or users of models,
worked in academia and industry, and came from several
countries in North America and Europe. The task force
met on three occasions, conducted frequent correspon-
dence and exchanges of drafts by electronic mail, and
solicited comments on three drafts from a core group of
external reviewers and more broadly from the member-
ship of ISPOR.
Results: Criteria for assessing the quality of models fell
into three areas: model structure, data used as inputs to
models, and model validation. Several major themes cut
across these areas. Models and their results should be rep-
resented as aids to decision making, not as statements 
of scientiﬁc fact; therefore, it is inappropriate to demand
that models be validated prospectively before use.
However, model assumptions regarding causal structure
and parameter estimates should be continually assessed
against data, and models should be revised accordingly.
Structural assumptions and parameter estimates should
be reported clearly and explicitly, and opportunities for
users to appreciate the conditional relationship between
inputs and outputs should be provided through sensitiv-
ity analyses.
Conclusions: Model-based evaluations are a valuable
resource for health-care decision makers. It is the respon-
sibility of model developers to conduct modeling studies
according to the best practicable standards of quality 
and to communicate results with adequate disclosure of
assumptions and with the caveat that conclusions are 
conditional upon the assumptions and data on which 
the model is built.
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ABSTRACT
Introduction
Mathematical modeling is used widely in economic
evaluations of pharmaceuticals and other health
care technologies. The purpose of modeling is to
structure evidence on clinical and economic out-
comes in a form that can help to inform decisions
about clinical practices and health-care resource
allocations.
Models synthesize evidence on health conse-
quences and costs from many different sources,
including data from clinical trials, observational
studies, insurance claim databases, case registries,
public health statistics, and preference surveys. A
model is a logical mathematical framework that
permits the integration of facts and values and that
links these data to outcomes that are of interest to
health-care decision makers. For decisions about
resource allocation, the end result of a model is
often an estimate of cost per quality-adjusted life
year (QALY) gained or other measure of value-
for-money.
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Although evidence from randomized clinical
trials (RCTs) remains central to efﬁcacy testing,
taken alone it can be misleading if endpoints are not
translated into measures that are valued by patients,
providers, insurers, and the general public. For
example, suppose that an RCT demonstrates that 
a treatment reduces the risk of a rare sequela of a
chronic disease by 50%. Further, suppose that
another trial shows that a different treatment
reduces the risk of a different, more common,
sequela by 10%. The latter intervention may well
be more effective, and cost-effective, than the
former, but a simple comparison of the trial results
would not sufﬁce. However, a model could be
helpful in revealing that fact to decision makers.
The comparison between the two interventions
would depend on a synthesis of evidence on the inci-
dence of the sequelae in the target population, the
relative risk reductions offered by treatment, sur-
vival and quality of life with and without the seque-
lae, and the costs of the interventions and the
medical care required to diagnose and treat the
sequelae.
The value of a model lies not only in the results
it generates, but also in its ability to reveal the
logical connection between inputs (i.e., data and
assumptions) and outputs in the form of valued
consequences and costs. For this reason, a model
should not be a “black box” for the end-user but
be as transparent as possible, so that the logic
behind its results can be grasped at an intuitive
level. Also for this reason, model results should
never be presented as point estimates or as uncon-
ditional claims of effectiveness or cost. Instead, the
outputs of models should be represented as condi-
tional upon the input data and assumptions, and
they should include extensive sensitivity analysis to
explore the effects of alternative data and assump-
tions on the results.
The purpose of this article is to state a consen-
sus position of the ISPOR Task Force on Good
Research Practices—Modeling Studies. Like models
themselves, this position represents the best judg-
ment of the Task Force at this time, and is subject
to change as new technologies for modeling emerge,
through advances in computing and analysis, and
as fundamentally new dimensions of health-care
technology and the environment, such as genomic
or microbial resistance to drugs, become more 
pervasive.
Task Force Process
The Chair of the ISPOR Task Force on Good
Research Practices—Modeling Studies, Milton C.
Weinstein, was appointed in 2000 by the Chairman
of the ISPOR Health Sciences Committee, Bryan R.
Luce. The members of the Task Force were invited
to participate by the Chair, with advice and consent
from the ISPOR Board of Directors. We sought 
individuals who were experienced as developers or
users of pharmacoeconomic models; who were rec-
ognized as scientiﬁc leaders in the ﬁeld; who worked
in academia, industry, and as advisors to govern-
ments; and who came from several countries. A ref-
erence group of ISPOR members was also identiﬁed
as individuals from whom comments would be
sought. The Task Force held its ﬁrst meeting at 
the Annual North American Scientiﬁc Meeting of
ISPOR in Arlington, Virginia, in May 2000. The
Task Force utilized electronic mail to exchange out-
lines and ideas during the subsequent months. A
draft report was prepared by the Chair and circu-
lated to the Task Force members for revision and
additional comment. The revised draft was circu-
lated to the reference group, and after receiving
their comments, another draft was prepared. A
summary of this draft was presented at a plenary
session of the Annual North American Scientiﬁc
Meeting of ISPOR in Arlington, Virginia, in May
2001. Comments from the audience were incorpo-
rated into a newly revised draft, which was posted
on the ISPOR Web site for general comment. The
next draft was presented at the Annual European
Scientiﬁc Meeting of ISPOR in Cannes, France, in
November 2001, and a revised draft was posted 
for further comment on the ISPOR Web site. This
report reﬂects the input from all of these sources of
comment.
Model Deﬁned
The National Research Council, in its report on the
uses of microsimulation modeling for social policy,
offered this deﬁnition of a simulation model: “. . .
a replicable, objective sequence of computations
used for generating estimates of quantities of
concern. . .” [1]. We deﬁne a health-care evaluation
model as an analytic methodology that accounts for
events over time and across populations, that is
based on data drawn from primary and/or sec-
ondary sources, and whose purpose is to estimate
the effects of an intervention on valued health con-
sequences and costs.
As part of our working deﬁnition, we assume
that cost-effectiveness models are meant to be aids
to decision making. This means that their purpose
is not to make unconditional claims about the con-
sequences of interventions, but to reveal the relation
between assumptions and outcomes. These assump-
tions include structural assumptions about causal
linkages between variables; quantitative parameters
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such as disease incidence and prevalence, treatment
efﬁcacy and effectiveness, survival rates, health-
state utilities, utilization rates, and unit costs; and
value judgments such as the nature of the conse-
quences that are valued by decision makers. A good
study based on a model makes all of these assump-
tions explicit and transparent and states its conclu-
sions conditionally upon them.
Model Evaluation
Models should be used only after careful testing to
ensure that the mathematical calculations are accu-
rate and consistent with the speciﬁcations of the
model (internal validity), to ensure that their inputs
and outputs are consistent with available data (cal-
ibration), and to ensure that their results make sense
and can be explained at an intuitive level (face valid-
ity). To the extent that different models of the same
decision come to different conclusions, modelers
should also be expected to explain the sources of
the differences (cross-validation). The description 
of the model should be sufﬁciently detailed that the
model can be replicated mathematically.
Tests of predictive validity—the ability of the
model to make accurate predictions of future
events—are valuable, but not absolutely essential.
Since future events convey information that is not
available at the time the model is developed and cal-
ibrated, a model should not be criticized for failing
to predict the future. However, a good model
should be susceptible to recalibration or respeciﬁ-
cation to adapt to new evidence as it becomes avail-
able. The criterion for determining whether, and to
what degree, tests of predictive validity are required
before model use depends on the beneﬁts in terms
of improving the model for decision making and the
costs of delaying the ﬂow of information while
obtaining the additional data [2].
Assessing the Quality of Models
The remainder of this statement describes the con-
sensus of the Task Force regarding the attributes
that deﬁne a good health-care decision model. We
borrow heavily from several excellent papers that
propose criteria for assessing the quality of models
[3–6]. The attributes are organized under the major
headings of structure, data, and validation.
Structure
1. The model should be structured so that 
its inputs and outputs are relevant to the 
decision-making perspective of the economic
evaluation. Both costs and health conse-
quences should reﬂect the chosen decision-
making perspective. For example, if the study
is meant to assist decision makers in allocat-
ing resources across a broad range of health
interventions at the societal level, then the
outputs of the model should be broadly
applicable, and important costs and conse-
quences for all members of the affected popu-
lation should be included. If a perspective
narrower than societal is used, then the report
should discuss, at least qualitatively, the impli-
cations of broadening the perspective to the
societal perspective.
2. The structure of the model should be consis-
tent both with a coherent theory of the health 
condition being modeled and with available
evidence regarding causal linkages between
variables. This does not mean that all causal
linkages must have been proven, as is com-
monly understood in tests of hypotheses by
showing that the effect size is statistically sig-
niﬁcant at a generally accepted level of signif-
icance (e.g., P < .05). Instead, it does mean 
that the linkages assumed are not contradicted
by available evidence and are consistent with
widely accepted theories.
3. If evidence regarding structural assumptions is
incomplete, and there is no universally
accepted theory of disease process, then the
limitations of the evidence supporting the
chosen model structure should be acknowl-
edged. If possible, sensitivity analyses using
alternative model structures—for example,
using alternative surrogate markers or inter-
mediate variables—should be performed.
Items 4–8 relate to state-transition (or compart-
mental or Markov) models:
4. Health states may be deﬁned to correspond 
to the underlying disease process, which may
be unobserved or unobservable, to observed
health status, or to a combination of both. For
example, screening models may deﬁne health
states based on underlying pathology, on clin-
ical status, or both. However, care should be
taken to avoid structural bias when interven-
tions modify both the underlying disease and
the clinical presentation, as, for example, in
models of cancer screening in which cases of
detected cancer may have different prognoses
depending on the method or frequency of
screening. In general, structural bias is avoided
by modeling underlying disease states and
then by calibrating outputs to data on
observed clinical status.
5. When transition rates or probabilities depend
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on events or states that may have been expe-
rienced in prior time periods, this dependence,
or “memory,” should be reﬂected in the
model. This may be done either by incorpo-
rating clinical or treatment history in the def-
inition of health states or by including history
as a covariate in specifying the transition
probabilities.
6. States should not be omitted because of lack
of data. Examples might be chronic health
states corresponding to uncommon adverse
events or disease sequelae that are not
observed within clinical trials. However, inclu-
sion of a health state should be based on evi-
dence consistent with recommendation 2
above.
7. Reasons to include additional subdivisions 
of health states may be based on their clinical
importance, their relation to mortality, their
relation to quality of life or patient prefer-
ences, their relation to resource costs, or any
combination. Disease states that may not be
considered clinically important may well be
important to include separately in the model
for these other reasons. Conversely, health
states that are regarded as having clinical
importance may be included to enhance face
validity, even if they do not materially affect
the model’s results.
8. The cycle length of the model should be short
enough so that multiple changes in pathology,
symptoms, treatment decisions, or costs
within a single cycle are unlikely. The choice
of cycle length should be justiﬁed.
9. The structure of the model should be as simple
as possible, while capturing underlying essen-
tials of the disease process and interventions.
It is not necessary to model the full complex-
ity of a disease if the decision can be informed
by a more aggregated structure, in terms of
disease states or population subgroups. If sim-
pliﬁcations are made, these should be justiﬁed
on grounds that they would be unlikely to
materially affect the results of the analysis.
Sometimes a structural sensitivity analysis that
uses a less aggregated model can provide reas-
surance that the simpliﬁcations do not mate-
rially affect the results.
10. Options and strategies should not be strictly
limited by the availability of direct evidence
from clinical trials. Neither should the range 
of modeled options and strategies be limited 
by currently accepted clinical practice. There
should be a balance between including a broad
range of feasible options and the need to keep
the model manageable, interpretable, and 
evidence-based.
11. While the structure of the model should reﬂect
the essential features of the disease and its
interventions irrespective of data availability,
it is expected that data availability may affect
choices regarding model structure. For ex-
ample, if a particular staging system has been
used most frequently in clinical studies, then
health states might well be deﬁned according 
to that staging system even if other staging
systems perform better in terms of predicting
outcomes or in terms of differentiating quality
of life and cost.
12. Failure to account for heterogeneity within the
modeled population can lead to errors in
model results. When appropriate, modeled
populations should be disaggregated accord-
ing to strata that have different event proba-
bilities, quality of life, and costs. This is
particularly important when recurrent event
rates over time are correlated within subpop-
ulations that have different event rates, since
failure to do so can lead to biased estimates of
long-term outcomes.
13. The time horizon of the model should be long
enough to reﬂect important and valued differ-
ences between the long-run consequences and
costs of alternative options and strategies.
Lifetime horizons are appropriate for many
models and are almost always required for
models in which options have different time-
varying survival rates. Shorter horizons may
be justiﬁed if survival and long-term chronic
sequelae do not differ among options or based
on an understanding of the disease process
and the effect of interventions. In any case, the
lack of long-term follow-up data should not
be used as a rationale for failing to extend the
time horizon as long as is relevant to the deci-
sion under analysis.
Data
Our recommendations on data inputs to models are
grouped into three categories: data identiﬁcation,
data modeling, and data incorporation.
Data identiﬁcation
1. A model should not be faulted because existing
data fall short of ideal standards of scientiﬁc
rigor. Decisions will be made, with or without
the model. To reject the model because of
incomplete evidence would imply that a deci-
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sion with neither the data nor the model is
better than a decision with the model but
without the data. With the model, the available
evidence can be used in a logical way to inform
the decision; without the model, an opportunity
to utilize the available evidence within the
logical framework will have been forgone.
2. Systematic reviews of the literature should be
conducted on key model inputs. Evidence that
such reviews have been done, or a justiﬁcation
for failing to do so based on the adequacy and
generalizability of readily obtained data, should
accompany the model.
3. Ranges (i.e., upper and lower bounds) should
accompany base-case estimates of all input
parameters for which sensitivity analyzes are
performed. The choice of parameters for sensi-
tivity analysis is a matter of judgment by the
analyst, but failure to perform sensitivity analy-
sis on a parameter whose value could be dis-
puted leaves the conclusions open to question.
4. Speciﬁcation of probability distributions for
input parameters based on sampling uncer-
tainty and/or between-study variations may be
incorporated into formal probabilistic sensitiv-
ity analysis. This is not always necessary or
cost-effective, however. For purposes of assess-
ing input distributions, the preferred method-
ology is to use posterior distributions obtained
from formal meta-analyses and Bayesian analy-
sis, but practical considerations may lead to the
use of expert judgment (see item 7 below).
5. If known data sources are excluded from con-
sideration in estimating parameters, the exclu-
sion should be justiﬁed.
6. Data sources and results should not be rejected
solely because they do not reach generally
accepted probability thresholds deﬁning “sta-
tistical signiﬁcance” (e.g., P > .05). All evi-
dence, even if insufﬁcient to rule out
randomness as a cause, may be legitimately
incorporated into models. This is subject to the
proviso that uncertainty about the estimates is
disclosed and tested in sensitivity analyses and
that conclusions are clearly framed as condi-
tional upon the input estimates used.
7. Expert opinion is a legitimate method for
assessing parameters, provided either that these
parameters are shown not to affect the results
importantly or that a sensitivity analysis is
reported on these parameters with a clear state-
ment that results are conditional upon this
(these) subjective estimate(s). If expert opinion
is elicited, and the results are sensitive to the
elicitations, then the process of elicitation
should be disclosed in detail. Expert estimates
derived from formal methods such as Delphi or
Nominal Group techniques are preferred.
8. A case should be made that reasonable oppor-
tunities to obtain new additional data prior to
modeling have been considered. “Reasonable”
in this context means that the cost and delay
inherent in obtaining the data are justiﬁed by 
the expected value of the new information in 
the analysis. While formal methods of assessing
value of information exist, it is sufﬁcient to give
a heuristic argument as to why the current body
of evidence was optimal from the point of view
of informing current decisions. This can often
be accomplished using sensitivity analysis, to
show that reasonable ranges of data would lead
to qualitatively similar ﬁndings, or by arguing
that the cost and delay in obtaining the data are
not worth the forgone beneﬁts of acting on
current evidence.
Data modeling
1. Data modeling refers to the mathematical steps
that are taken to transform empirical observa-
tions into a form that is useful for decision
modeling. Examples include:
a. The method for incorporating estimates of
treatment effectiveness from clinical trials
with estimates of baseline outcomes from 
epidemiologic or public health data. Effec-
tiveness estimates may be based either on
intention-to-treat or on-treatment data,
depending on the objectives of the analysis.
Often, an appropriate approach is to derive
estimates of relative risk (or odds ratios)
between treatment options from clinical
trials and to superimpose these on estimates
of baseline (e.g., untreated or with conven-
tional treatment) probabilities of survival or
other endpoints from population-based
sources.
b. The method for transforming interval prob-
abilities from the literature or from a clini-
cal trial into an instantaneous rate and then
into a transition probability or event prob-
ability corresponding to the time interval
used in the model.
c. The method for combining disease-speciﬁc
and all-cause mortality into the model. In
general, it is acceptable to derive all-cause
mortality probabilities from national life
tables, unless an alternative source can be
justiﬁed. In general, it is not necessary to
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correct for the fact that all-cause mortality
includes disease-speciﬁc mortality in the
general population, unless the disease repre-
sents a major cause of death in the demo-
graphic groups being modeled.
d. The method for modeling survival (e.g., as
an exponential, gamma, Weibull, or Gom-
pertz distribution). The choice of functional
form for disease-speciﬁc mortality should be
speciﬁed and justiﬁed. In general, all-cause
mortality should be modeled nonparametri-
cally based on life table data.
e. Modeling risk factors or interventions as
having an additive or multiplicative effect 
on baseline probabilities or rates of disease 
incidence or mortality. Evidence supporting
either the additive or the multiplicative form
should be sought from studies that examine
the effect of the risk factor or intervention
in a population stratiﬁed by base risk.
f. The method for combining domain-speciﬁc
utilities into a multiattribute utility function.
It is preferable to use validated health-
related quality-of-life instruments with 
prespeciﬁed scoring systems based on
“forced-choice” methods (standard gamble,
time trade-off).
g. The method for transforming health status
values (such as rating scales or health-state
classiﬁcations) into quality-of-life weights.
h. The method for transforming charges to 
costs.
i. The method for adjusting for inﬂation or 
purchasing power across time and among
countries. Adjustment for inﬂation should
be based on the Consumer Price Index (CPI),
its health-care components, or one or more
of its subcomponents such as medical care
services or equipment. The choice between
the general CPI and its health-care compo-
nent or subcomponents depends on whether
the resources being priced are better repre-
sented by the general “market basket” in the
CPI or by the health-care market basket. A
limitation of the health-care CPI is that it
reﬂects not only the prices but also to some
degree the quantities of input resources used
to produce health-care services. The method
of choice for making adjustments across
countries is to use purchasing power parity.
However, a simple currency conversion
would be appropriate if there is an interna-
tional market for an input at a ﬁxed price.
j. The method for discounting costs and health
effects to present value.
2. Data modeling assumptions should be disclosed
and supported by evidence of their general
acceptance and, preferably, of their empirical
validity. Key steps taken in developing the
model should be carefully documented and
recorded. Model credibility may be enhanced
by showing how a model was conceived, for
example, before or during a phase III or IV clin-
ical trial, and how its structure and data inputs
evolved in light of new evidence (e.g., after
completion of a clinical trial) in response to
subsequent discussions with clinical, regulatory,
and policy experts.
3. When alternative, but equally defensible, data
modeling approaches may lead to materially
different results, sensitivity analyses should be 
performed to assess the implications of these
alternatives. For example, if a model predicts
smaller gains in life expectancy at older ages,
but the model uses a multiplicative speciﬁcation
of the effect of an intervention of baseline mor-
tality, then the alternative of an additive model
should be tested. If there is stronger empirical
evidence in support of one functional form,
then that form should be the base case and the
alternative form(s) should be tested in sensitiv-
ity analysis.
4. Data modeling methods should follow gener-
ally accepted methods of biostatistics and epi-
demiology. For modeling, meta-analysis is a
valid and desirable approach, provided that
care is taken to recognize heterogeneity among
data sources. Heterogenity can be considered
either by segregating estimates based on differ-
ent groupings of primary studies or by estimat-
ing formal hierarchical models to combine
information from heterogeneous studies.
Data incorporation
1. Measurement units, time intervals, and popu-
lation characteristics should be mutually con-
sistent throughout the model.
2. Either probabilistic (Monte Carlo, ﬁrst-order)
simulation or deterministic (cohort) simulation
is acceptable.
3. If ﬁrst-order, Monte Carlo simulation is used,
evidence should be provided that the random
simulation error (e.g., the standard deviation of
output values per run) is appreciably smaller
than the effect sizes of interest.
4. All modeling studies should include extensive
sensitivity analyses of key parameters. Either
deterministic (one-way and multiway) or prob-
abilistic sensitivity analyses are appropriate.
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5. When possible, sensitivity analyses within
models that use Monte Carlo simulations
should use ﬁxed random number “seeds”
within each sensitivity analysis, to minimize
random simulation error.
6. If cohort simulation is used, sensitivity analysis
may be done using probabilistic (Monte Carlo,
second-order) simulation, using the speciﬁed
probability distributions of parameter inputs. 
In specifying those parameter distributions,
care should be taken to ensure that interdepen-
dence among parameters is reﬂected properly in
the joint distribution of parameters.
7. When appropriate, and if the differences in
quality-adjusted survival between alternatives
are less than one cycle length, the half-cycle cor-
rection should be used to adjust time-related
estimates in the model.
Validation
Our recommendations on validation of models are
grouped into three categories: internal validation,
between-model validation, and external validation.
Internal validation
1. Models should be subjected to thorough inter-
nal testing and “debugging.” Evidence that this
has been done should be provided. This process
should include using null or extreme input
values to test whether they produce the
expected outputs. It may also include examina-
tion of the program code for syntactical errors,
and tests of replication using equivalent input
values.
2. Models should be calibrated against data when
possible. Calibration is possible when there
exist data on both model outputs and model
inputs, over the time frame being modeled. Cal-
ibration data can come from national health
statistics, such as aggregate and age–sex-spe-
ciﬁc numbers of deaths, hospitalizations, pro-
cedures, or resource costs. The calibration data
should be from sources independent of the data
used to estimate input parameters in the model.
A model should not be criticized if independent
calibration data do not exist. However, a model
is subject to criticism if independent data suit-
able for validation do exist and either the model
fails to produce outputs consistent with those
data (or discrepancies cannot be explained) or
the modeler has not examined the concordance
between model outputs and such data.
3. While the source code should generally remain
the property of the modeler, reasonable
requests for copies of models with adequate
user interface should be made available for peer
review purposes, under conditions of strict
security and protection of property rights.
Between-model validation
1. Models should be developed independently
from one another, to permit tests of between-
model corroboration (convergent validity).
2. If a model’s outputs differ appreciably from 
published or publicly available results based on
other models, the modeler should make a
serious effort to explain the discrepancies. Are
the discrepancies due to differences in model
structure or input values?
3. Modelers should cooperate with other model-
ers in comparing results and articulating the
reasons for discrepancies. (We applaud funding
agencies that support this type of collaboration,
e.g., the CISNET program of cancer modeling
supported by the US National Cancer Institute.)
External and predictive validation. Models should
be based on the best evidence available at the time
they are built. In areas such as HIV and hyperlipi-
demia, early models assumed that health conse-
quences are mediated by risk factors (CD4 cell
counts, serum cholesterol). Subsequent data from
some clinical trials have been found to be at vari-
ance with the estimates from initial models, while
others are consistent with the model assumptions.
Insights from clinical trials have led to a second gen-
eration of models in both HIV and hyperlipidemia,
the estimates from which track more closely with
those of the clinical trials. In HIV, this has been
accomplished by incorporating antiretroviral drug
resistance into treatment efﬁcacy estimates and HIV
RNA as a marker of disease virulence; in hyperlipi-
demia, this has been accomplished by modeling 
the lipid fractions LDL and HDL as risk factors.
Remaining discrepancies between direct empirical
evidence and model results are unexplained.
Whether these relate to artifacts of clinical trial
design (e.g., patient selection, treatment crossovers)
or underlying biological factors (e.g., C-reactive
protein and statins, immunologic recovery and anti-
retroviral therapy) is still unknown. Models there-
fore not only capture the understanding of the
science at the time the model is constructed (at a
time when there still might be limited long-term
data on new treatment), but they can also provide
a basis for contrasting and interpreting information
from new studies. The ability of models to adapt to
new evidence and scientiﬁc understanding should be
regarded as a strength, not as a weakness, of the
modeling approach.
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1. Since models are intended as aids to current
decision making, and since their outputs should
be reported as conditional upon the input
assumptions, it is not necessary that every data
estimate or structural assumption be tested in
prospective studies, in advance of model use.
2. The decision to obtain additional data to
inform a model should be based on a balance
between the expected value of the additional
information and the cost of the information.
a. The “expected value of information” refers 
to the decision-theoretic concept which
values information in terms of its expected
(or average) effect on the consequences of
decisions. For example, the expected value
of information would be zero for a study of
a model parameter whose prior range does
not include the threshold for the choice
among decision options. Judgment concern-
ing prior probabilities of possible study
results is inevitably part of the assessment of
“expected value of information.”
b. The “cost of the information” includes the
resource cost of performing an empirical
study or trial, as well as the expected
forgone beneﬁts of delaying decisions until
the study or trial is completed. Judgment
concerning prior probabilities of treatment
effects is inevitably part of the assessment of
cost of information.
c. Recommendations for the conduct or design
of research investigations to guide future
decision making can be based on formal
analysis of the value of information or on
informal interpretation of the implications
of sensitivity analyses.
3. Models should never be regarded as complete
or immutable. They should be repeatedly
updated, and sometimes abandoned and
replaced, as new evidence becomes available to
inform their structure or input values. As a
corollary, models that have been shown to be
inconsistent with subsequent evidence, but that
have not been revised to calibrate against or
incorporate this new evidence, should be 
abandoned until such recalibration has been
accomplished.
Concluding Comments
While these guidelines represent the views of this
Task Force at this time, they should not be regarded
as rigid or cast in stone. This is not a “rule book.”
Different circumstances will lead to deviations from
these guidelines, depending on resources available
to the modeler (time, money, and data) and on the
purpose of the model.
In our view, the most important thing to keep in
mind in evaluating a health-care evaluation model
is that its outputs must not be regarded as claims
about the facts or as predictions about the future.
Rather, its purpose is to synthesize evidence and
assumptions in a way that allows end users to gain
insight into the implications of those inputs for
valued consequences and costs. Its outputs are
always contingent on its inputs, which is why it is
so important that its inputs be as transparent and
accessible as is practical.
Further Reading on Modeling Methodology
The purpose of this report is not to provide an
overview of modeling methodology, but rather to
identify those aspects of methodology that the Task
Force regards as good research practice. We recom-
mend the following sources for readers who wish to
acquaint themselves with the basics of modeling
methods. For an introductory textbook on decision
analysis, including decision trees and Markov
models, see Hunink et al. [7]. For contemporary
methods of modeling in economic evaluations,
including an overview of methods for modeling sur-
vival from trial data, and an overview of deter-
ministic and stochastic approaches to modeling, 
see Kuntz and Weinstein [8]. For an overview of
methods for handling uncertainty in models, see
Briggs [9] and Chapter 11 of Hunink et al. [7].
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